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Prostaglandin (PG) H synthases (PGHS) or cyclooxygenases (COX) catalyse the peroxidation of arachi-
donic acid (AA) to PGG2 and PGH2 which are further converted to a series of prostaglandins and
thromboxane A2. Here, we report that GSH promotes concomitant formation of the current oxida-
tive stress biomarkers malondialdehyde (MDA) and 15(S)-8-iso-prostaglandin F2a from AA via PGHS.
This illustrates an uncommon interplay of enzymatic and chemical reactions to produce species that
are considered to be exclusively produced by free-radical-catalysed reactions. We propose mecha-
nisms for the PGHS/AA/GSH-dependent formation of MDA, 15(S)-8-iso-prostaglandin F2a and other
F2-isoprostanes. These mechanisms are supported by clinical observations.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Glutathione (GSH) is one of the most important and most
abundant intra-cellular endogenously produced antioxidants. The
chemical reaction of the sulfhydryl (SH) group of GSH with oxi-
dants such as hydrogen peroxide (H2O2) yields glutathione disul-
phide (GSSG) and water. GSSG is also formed by transition metal
ions-catalysed oxidation of GSH. In well-functioning cells, GSSG
is effectively reduced to GSH by glutathione reductase, so that
the molar ratio of GSH to GSSG (GSH/GSSG) is in great favour of
GSH, e.g., about 750:1 in human blood [1] and 200:1 in human
erythrocytes [2]. The intra-cellular GSH/GSSG molar ratio is there-
fore a widely used quantitative parameter of oxidative stress in
health and disease [3,4].
Yet, GSH is not merely an antioxidant but it also serves as a
cofactor/substrate for various enzymes, for instance for GSH
S-transferases. In most of these cases GSH is consumed without
forming GSSG. In case of intoxication by certain xenobiotica, such
as paracetamol (acetaminophen) overdose, considerable amounts
of GSH are consumed. In such cases GSH must be substituted by
intravenous administration of large amounts of N-acetylcysteinechemical Societies. Published by E
cal Pharmacology, Hannover
, Germany. Fax: +49 511 532
D. Tsikas).(NAC). On the other hand, conversion of endogenously produced
substances, such as the arachidonic acid-derived epoxide leukotri-
ene A4 (LTA4) to the cysteinyl leukotriene C4 (LTC4), requires only
very low GSH amounts. This also applies to the prostaglandin
(PG) H synthase (PGHS)-catalysed oxidation of arachidonic acid
(AA) to a variety of PGs and thromboxane A2 (TxA2) which are pres-
ent in pM-concentrations in biological ﬂuids and tissues [5].
The PGHS isoforms, PGHS-1 and PGHS-2, are commonly
referred to as cyclooxygenase-1 (COX-1) and cyclooxygenase-2
(COX-2), respectively. It has been demonstrated that GSH is oxi-
dised to its thiyl free radical metabolite by PGHS [6]. Also, GSH is
involved in the metabolism of PGs and can inhibit PGHS activity
[5,7]. Especially in human platelets, formation of TxA2 has been
reported to be accompanied by temporary formation of GSSG,
malondialdehyde (MDA) and the complementary 12-hydroxy-
5,8,10-heptadecatrienoic acid (HHTrE) in considerable amounts
[8–11]. Yet, the mechanisms leading to GSSG formation during
PGHS-catalysed AA peroxidation are incompletely understood.
Despite increasingly use of F2-isoprostanes including 15(S)-8-
iso-prostaglandin F2a (15(S)-8-iso-PGF2a) as biomarkers of oxida-
tive stress [12], MDA is still one of the most widely measured
biomarkers of oxidative stress [3,4]. In accordance with the cur-
rently prevailing theory of oxidative stress, the antioxidant GSH
should prevent lipid peroxidation. Consequently, GSH should keep
low the concentration of oxidative stress biomarkers. The relation-
ship between MDA, 15(S)-8-iso-PGF2a, PGHS and GSH, and itslsevier B.V. All rights reserved.
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Fig. 1. Formation of MDA (A) and 15(S)-8-iso-PGF2a (B) in incubation mixtures of
AA (10 lM) and PGHS-1 (1.4 nM) or PGHS-2 (10.7 nM) at varying GSH concentra-
tions (0–1000 lM) at 37 C for 30 min under aerobic conditions. (C) Linear
relationship between MDA and 15(S)-8-iso-PGF2a measured in this experiment.
Data are shown as mean ± S.D. from three independent experiments (A) and as the




Fig. 2. PGHS-1-dependent formation of GSSG upon incubation of GSH in the assay
buffer under various conditions. (A) GSSG formation from GSH (100 lM) upon a 5-
min pre-incubation with various PGHS-1 concentrations followed by addition of AA
either at 0 lM or 10 lM and subsequent incubation for 30 min. (B) GSSG formation
from GSH (100 lM) upon a 5-min pre-incubation with PGHS-1 (10 U), AA (10 lM)
and subsequent incubation for 30 min. (C) GSSG formation from GSH (100 lM)
upon a 5-min pre-incubation with PGHS-1 (10 U), acetylsalicylic acid (ASA,
1000 lM) or diclofenac (Diclo, 1 lM) followed by addition AA (10 lM) and
subsequent incubation for 30 min. Data are shown as the mean from two
independent experiments (A and B) and as mean ± S.D. from three independent
experiments (C).
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present study, we investigated a possible role of GSH in the forma-
tion of PGHS-dependent formation of MDA and 15(S)-8-iso-PGF2a.Paradoxically, we observed that GSH does not prevent but it pro-
motes PGHS-dependent MDA and 15(S)-8-iso-PGF2a formation
from AA in vitro. Based on these ﬁndings we propose mechanisms
for the interaction between GSH and PGHS in the peroxidation of
AA to MDA, 15(S)-8-iso-PGF2a, TxA2 and other metabolites.
AB
Fig. 3. (A) PGHS-1 (1.4 nM) and (B) PGHS-2 (10.7 nM) dependent formation of MDA
from AA (10 lM) upon incubation (30 min) of GSH at 0 lM (-GSH) or 100 lM in the
absence (Control) or in the presence of the PGHS inhibitors acetylsalicylic acid (ASA;
1000 lM), diclofenac (Diclo; 1 lM), ibuprofen (Ibu; 1 lM) or indomethacin (Indo;
1 lM). Data are shown as mean ± S.D. from three independent experiments.
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2.1. Materials
Arachidonic acid, [5Z,6,8Z,9,11Z,12,14Z,15-2H8]-arachidonic
acid (d8-AA; 99.5 atom% 2H), acetylsalicylic acid (ASA), diclofenac,
ibuprofen and indomethacin were obtained from Sigma (Munich,
Germany). Recombinant ovine PGHS-1 (http://www.caymanchem.
com/pdfs/60100.pdf) and recombinant ovine PGHS-2 (http://www.
caymanchem.com/pdfs/60120.pdf), 2H4-15(S)-8-iso-PGF2a, other
2H-labelled prostaglandins and 2H-labelled thromboxane B2, and
immunoafﬁnity column chromatography (IAC) cartridges with
immobilized antibodies raised against 15(S)-8-iso-PGF2a (http://
www.caymanchem.com/app/template/Product.vm/catalog/400058)
or PGE2 (https://www.caymanchem.com/pdfs/500450.pdf) were
obtained from Cayman Chemicals (Ann Arbor, MI, USA). These
materials were used as received and in accordance with the
manufacturer’s recommendations.
2.2. In vitro studies
All PGHS-catalysed reactions and respective controls were per-
formed under aerobic conditions at 37 C in 100 mM sodium/
potassium phosphate buffer (pH 8.0) that contained 2 mM phenol,
5 mM EDTA and 1 lM hematin. These conditions are recom-
mended by the manufacturer and were proven to be optimal in
our experiments. The reaction was started by adding AA at a ﬁnal
concentration of 10 lM, which is close to the KM values towards
PGHS-1 (10 lM) and PGHS-2 (2.5 lM) as observed in preliminary
experiments. Reaction mixtures were incubated for 30 min or as
reported in the respective experiments. For the sake of clarity,
experimental conditions are detailed in the ﬁgure legends. In our
study, all PGHS inhibitors were used at pharmacologically relevant
concentrations being close to their reported IC50 values (see
Section 3).
For MDA analysis in PGHS incubation mixtures, 100-lL aliquots
were taken from the reaction mixtures and immediately treated
with 400-lL aliquots of ice-cold acetone to stop enzymatic reac-
tions. Subsequently, the internal standard [1,3-2H2]-MDA was
added (1 lM) and derivatization and GC–MS/MS analysis were
performed as described elsewhere [13]. For 15(S)-8-iso-PGF2a anal-
ysis 100-lL aliquots were taken from the reaction mixture and
immediately acidiﬁed to pH4.5. Subsequently, the internal standard
2H4-15(S)-8-iso-PGF2a was added (1.75 nM), the analytes were ex-
tracted by IAC, derivatized and analysed by GC–MS/MS [13,14].
Other prostaglandins were also analysed by GC–MS/MS [14] after
solvent extractionwith ethyl acetate fromacidiﬁed (pH4.5) samples
using their respective 2H-labelled analogues (1 nM). GSSG was
quantitated by HPLC with UV absorbance detection at 205 nm [15].
Data from other experiments are shown as the mean from two
independent experiments or mean ± S.D. from three independent
experiments.
2.3. In vivo studies
To examine the relationship between plasma concentrations of
the oxidative stress biomarkers MDA and 4-hydroxy-2-nonenal
(HNE), we analysed plasma samples from 15 males and ﬁve fe-
males subjects (age 68 ± 8 years) suffering from peripheral arterial
occlusive disease. These samples were obtained on 2 days with an
interval of 90 days between. Plasma MDA, HNE and total
15(S)-8-iso-PGF2a (i.e., free + esteriﬁed fractions) were measured
by GC–MS/MS [13,14]. The study was approved by the Ethics Com-
mittee of the Hannover Medical School.
In a randomized, placebo-controlled clinical trial in patients
undergoing cardiac surgery study we showed previously thatintravenously administered NAC prevented formation of reactive
oxygen and reactive nitrogen species in transmural left ventricular
biopsy specimens [16]. In that study patients had been treated
with NAC (NAC group; prime 100 mg/kg into cardiopulmonary by-
pass, followed by infusion 20 mg  kg1  h1) or placebo (CON
group) immediately before (NAC0h, CON0h) and at the end of the
surgery (3 h; NAC3h, CON3h), as well as 24 h after surgery
(NAC24h, CON24h). In urine samples collected from this study,
15(S)-8-iso-PGF2a and PGE2 (i.e., 15(S)-PGE2) were quantiﬁed by
GC–MS/MS after IAC. Data from this study are shown as mean
± S.E.M. Statistical signiﬁcance was tested by t test.
3. Results
3.1. In vitro studies
Fig. 1 shows that formation of MDA and 15(S)-8-iso-PGF2a from
PGHS-catalysed peroxidation of AA is dependent upon GSH. In the
PGHS-1 and PGHS-2 incubation mixtures, MDA concentrations
were 200–250 times higher than 15(S)-8-iso-PGF2a concentrations
(Fig. 1C). There were highly linear relationships (r > 0.9) between
MDA and 15(S)-8-iso-PGF2a concentrations for both isozymes. Be-
cause MDA is a C3-compound (i.e., C3H4O) and 15(S)-8-iso-PGF2a is
a C20-compound (i.e., C20H34O5), MDA and 15(S)-8-iso-PGF2a must
originate from two AA (a C20-compound, i.e., C20H32O2) molecules.
In agreement with previous reports [5,7,17], we found that GSH
Fig. 4. GC–MS spectrum of the pentaﬂuorobenzyl derivative of the reaction product obtained from the incubation of 10 lM [5,6,8,9,11,12,14,15-2H8]-arachidonic acid (d8-AA)
with PGHS-2 (10.7 nM) in the presence of GSH (100 lM) for 30 min at 37 C. The insert on the left shows the GC–MS spectrum of the pentaﬂuorobenzyl derivative of synthetic
d2-MDA [13]. Both mass spectra were obtained from the gas chromatographic peak with the same GC retention time of 5.9 min. GSHmediated PGHS-2-catalysed formation of
two distinctly 2H-labelled MDA species, i.e., d1-MDA (m/z 252) and d2-MDA (m/z 253). d8-AA was used immediately after its receipt from the supplier.
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PGE2 formation rate (data not shown).
In GSH-containing PGHS incubation mixtures, we observed for-
mation of GSSG (Fig. 2). GSSG formation required presence of both,
PGHS and AA, and was dependent upon PGHS concentration and
incubation time (Fig. 2). Substitution of GSH by cysteine (Cys) re-
vealed formation of cystine, i.e., the Cys disulphide, at concentra-
tions similar to those of GSSG (i.e., up to 4 lM; data not shown).
These observations suggest that the effects of GSH and Cys are
chemical in nature. In the presence of the irreversible PGHS inhib-
itor acetylsalicylic acid (ASA, 1000 lM), GSSG was formed at lower
concentrations (Fig. 2C). In contrast, in the presence of the revers-
ible PGHS inhibitor diclofenac (1 lM), GSSG formation occurred
and was comparable to control, i.e., in the absence of any PGHS
inhibitor (Fig. 2C). Thus, GSH oxidation to GSSG occurs during
PGHS-catalysed oxidation of AA, presumably during the peroxidase
reaction of PGHS [11], and not simply by GSH autoxidation.
In vitro, PGHS-catalysed and GSH-promoted formation of MDA
and 15(S)-8-iso-PGF2a (not shown) was inﬂuenced differently bythe COX inhibitors tested. Thus, PGHS-catalysed formation of
MDA could not be completely blunted by the irreversible COX
inhibitor ASA (1000 lM; IC50 0.75 and 1.25 mM for the recombi-
nant PGHS-1 and PGHS-2 isoforms), by the reversible COX inhibi-
tors diclofenac (1 lM; IC50 60–220 nM), ibuprofen (1 lM; IC50
9 lM) or indomethacin (1 lM; IC50 0.1–6 lM) (Fig. 3). ASA and
indomethacin inhibited PGHS-2-catalysed formation of MDA with
no effect on PGHS-1. By contrast, ibuprofen inhibited PGHS-1-
catalysed formation of MDA but was inactive towards PGHS-2.
COX inhibitors exert their action on different sites of the PGHS
enzymes and inhibit their activity by different mechanisms. The
distinct effects of the COX inhibitors tested in this study may
indicate that GSH intervenes at different stages of the multi-step
and complex process of PGHS-catalysed peroxidation of AA (see
Section 4 and Supplement).
To gain mechanistic insight into the PGHS-dependent, GSH-
mediated formation of MDA from AA, we investigated the
PGHS-2-catalysed oxidation of the deuterium-labelled [5,6,8,
9,11,12, 14,15-2H8]-arachidonic acid (d8-AA). By means of a
AB
Fig. 5. Relationship between concentrations of (A) MDA and total 15(S)-8-iso-PGF2a
(i.e., free and esteriﬁed to lipids) and of (B) HNE and MDA in plasma of 15 males and
ﬁve females subjects (age 68 ± 8 years) suffering from peripheral arterial occlusive
disease. Note the different concentration units for MDA and HNE (i.e., lM), and for
15(S)-8-iso-PGF2a (i.e., nM). Plasma was analysed on 2 days with an interval of
90 days between. Insets are the regression equations, r and P values from linear
regression analysis of (A) MDA (y) vs. 15(S)-8-iso-PGF2a (x) and of (B) HNE (y) vs.
MDA (x).
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rium-labelled MDA species: [1,3-2H2]MDA (d2-MDA) and
[1-2H]MDA (d1-MDA) (Fig. 4). Formation from d8-AA of MDA with
two deuterium atoms (i.e., d2-MDA) and one deuterium atom (i.e.,
d1-MDA) at comparable concentration, as indicated by the equallyTable 1
Creatinine-corrected urinary excretion of 15(S)-8-iso-PGF2a and 15(S)-PGE2 and their mola
NAC, while ‘‘CON’’ group receive placebo.
Group 15(S)-8-iso-PGF2a (nmol/mol creatinine) 15(S)-PGE2 (nmol/mol c
NAC0h 40.5 ± 10.7 (19) 103.1 ± 37.6 (18)
NAC3h 76.3 ± 10.2 (19) 166.2 ± 30.2 (19)
NAC24h 46.1 ± 7.18 (19) 24.9 ± 5.24 (19)
CON0h 37.8 ± 8.02 (18) 54.5 ± 9.88 (17)
CON3h 57.2 ± 10.3 (18) 133.8 ± 30.7 (17)
CON24h 32.8 ± 3.70 (17) 18.8 ± 2.85 (18)
a Data are shown as mean ± S.E.M. In parentheses, the number of considered patients
b Urine samples were collected at three different time points (0 h, 3 h and 24 h).
c There was no signiﬁcant difference between the groups at each time point.intense ions atm/z 252 andm/z 253 (Fig. 4), implies rearrangement
of the double bond system of AA during its oxidation by PGHS-2
and/or during the subsequent steps. This is supported by the
observation of PGE2, AA and HHTrE labelled with 8, 7 and 6
deuterium atoms, and by the formation of deuterium-labelled
trans-arachidonic acid (Figs. S1–S3). trans-Arachidonic acid iso-
mers have been shown to occur physiologically in human plasma
[18] and to be formed from arachidonic acid added to human
platelets [19].
3.2. In vivo studies
Like in vitro with the recombinant PGHS isoforms (Fig. 1C),
in vivo in plasma samples of humans we observed a close correla-
tion between MDA and 15(S)-8-iso-PGF2a concentrations, as well
as between HNE and MDA concentrations (Fig. 5). That MDA and
HNE occur in human plasma at concentrations of the same order
of magnitude may suggest that MDA and HNE are formed from
the same AA molecule by a common PGHS/AA/GSH-involving
mechanism (see Section 4).
Many in vivo and in vitro studies reported that the F2-isopros-
tane 8-iso-PGF2a is produced by PGHS [19–28], while PGF2a, which
is generally accepted to be exclusively produced by PGHS, is pro-
duced independently of PGHS [29]. In urine samples collected from
a previously performed study [30] on 15 healthy young volunteers
who had received celecoxib, a PGHS-2 selective inhibitor, indo-
methacin, a non-selective PGHS inhibitor, or placebo, we measured
retrospectively 15(S)-8-iso-PGF2a. We found that excretion of
15(S)-8-iso-PGF2a was reduced tendentiously both by celecoxib
(32.7 ± 3.17 nmol/mol creatinine; P = 0.097) and indomethacin
(34.9 ± 3.74 nmol/mol creatinine; P = 0.162) compared to placebo
(45.5 ± 7.25 nmol/mol creatinine). This observation collaborates
with previous ﬁndings [19–28] and argues for PGHS-catalysed for-
mation of 15(S)-8-iso-PGF2a.
NAC, a precursor of GSH, and ascorbic acid (vitamin C) have
been widely used as antioxidants with contradictory outcomes.
For instance, NAC (10 mg/kg body weight) and ascorbic acid
(12.5 mg/kg body weight) increased the plasma concentration of
15(S)-8-iso-PGF2a, suggesting enhancement of oxidative stress in
exercising humans [29]. An alternative explanation for the increase
in plasma of 15(S)-8-iso-PGF2a concentration seen in the study by
Childs et al. [29] may be GSH- and/or ascorbic acid-promoted and
PGHS-mediated formation of 15(S)-8-iso-PGF2a. It is worth men-
tioning that ascorbic acid may mimic the action of thiols on PGHS
activity [31].
In patients undergoing cardiac surgery we showed that NAC
administration reduced tissue 3-nitrotyrosine content suggesting
reduction of nitrative stress by NAC and/or its metabolites includ-
ing GSH [16]. In urine samples collected in that study were mea-
sured retrospectively 15(S)-8-iso-PGF2a and PGE2. Table 1 shows
that both NAC and placebo increased temporarily excretion ofr ratioa in two groups of patients undergoing cardiac surgeryb. ‘‘NAC’’ group received
reatinine) 15(S)-8-iso-PGF2a to 15(S)-PGE2 ratio P value for the ratioc
0.74 ± 0.16 (18) 0.837 (0 h vs. 3 h)
0.71 ± 0.12 (19) 0.0015 (0 h vs. 24 h)
4.65 ± 1.28 (18) 0.0018 (3 h vs. 24 h)
0.958 ± 0.192 (15) 0.3079 (0 h vs. 3 h)
0.712 ± 0.136 (17) 0.0052 (0 h vs. 24 h)
3.549 ± 1.376 (17) 0.0003 (3 h vs. 24 h)
is given.
AB
Fig. 6. Proposed mechanisms for the GSH-induced formation of MDA and HNE (A), and of PGF2a, 15(S)-8-iso-PGF2a and other F2-isoprostanes (B) during PGHS-catalysed
peroxidation of AA. (A) GSH attacks the electropositive O atom at C-11 of the 9,11-peroxido group of an intermediate which, without the action of GSH, would provide PGG2. A
second GSH molecule reduces the S atom of the intermediate G–S(±0)–O–R (R, is a radical residue) to yield GSSG, while R rearranges to ﬁnally produce HNE. (B) In total six
GSH molecules are involved in the attack on electropositive (d+) O atoms of the 9,11-peroxido and 15-peroxido groups of the same intermediate as in (A) and the subsequent
reactions to produce three GSSG molecules and a AA-trihydroxy-diradical that rearranges to isomeric PGF2a, 15(S)-8-iso-PGF2a and other F2-isoprostanes.
3728 D. Tsikas et al. / FEBS Letters 586 (2012) 3723–373015(S)-8-iso-PGF2a and PGE2 in the urine. It is remarkable that
15(S)-8-iso-PGF2a values returned to baseline 24 h after surgery.
By contrast, PGE2 values decreased below baseline 24 h after
surgery. The effects were stronger in the NAC group (reduction
by 76%) than in the placebo group (reduction by 66%). As the pa-
tients of both groups had received several other drugs, it is possible
that the effects of NAC on PGHS-catalysed formation of 15(S)-8-iso-
PGF2a and inhibition of PGE2 have been superposed by actions of
the drugs.4. Discussion
The mechanisms by which 15(S)-8-iso-PGF2a, MDA, prostaglan-
dins including PGG2, PGH2, PGE2, PGD2 and PGF2a, and TxA2 are
formed during the PGHS-catalysed peroxidation of AA are still
incompletely understood. For TxA2 and MDA, Ullrich et al. pro-
posed an oxene transfer mechanism analogous to that catalysed
by cytochrome P450 [32]. Pace-Asciak and Smith suggested a
transient formation of an electropositive O atom at the C-11 and
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cause MDA (C3H4O), 15(S)-8-iso-PGF2a (C20H34O5) and TxA2
(C20H32O5) cannot be formed from a single AA molecule at the
same time, several different mechanisms and intermediates are
likely to be involved and might better explain differences in
MDA, GSSG and TxA2 (actually its stable analogue TxB2) concentra-
tions measured in vitro and in vivo. As the mechanism proposed by
Pace-Asciak and Smith are more compatible with the results re-
ported in the present article, we extended this mechanism by
including GSH as a chemical partner in the PGHS-catalysed perox-
idation of AA.
In accordance with this mechanism (Fig. 6), nucleophilic attack
of the GSH thiolate on the electropositive O atom at C-11 of the
9,11-peroxido group of an AA intermediate produces concomi-
tantly MDA and HNE in stoichiometric amounts (Fig. 6A). The per-
oxidised, not yet cyclised AA triradical intermediate is different
from PGG2, because GSH and other thiols do not convert PGG2 into
MDA (not shown), PGE2 (Fig. S5) and PGF2a (Fig. S5). On the other
hand, formation of PGF2a, 15(S)-8-iso-PGF2a and other F2-isopros-
tanes requires simultaneous nucleophilic attack of the SH groups
of two GSH molecules on both O atoms of the 9,11-peroxido group
of the peroxidised not yet cyclised AA triradical intermediate
(Fig. 6B). This mechanism requires the combination of the two rad-
ical C atoms at positions 8 and 12 (Fig. 6B). Such a ring closure is
likely to produce several isomeric compounds such as 15(S)-8-
iso-PGF2a and PGF2a, and possibly other F2-isoprostanes of the type
15-F2t-IsoP [12] after rearrangement of the AA-trihydroxy-
diradical. A similar mechanism may also apply to the other three
types of F2-isoprostanes, i.e., 5-F2t-IsoP, 8-F2t-IsoP and 12-F2t-IsoP.
Finally, formation of TxA2 requires nucleophilic attack of the SH
group of a GSH molecule on the electropositive O atom at C-9 of
the 9,11-peroxido group of PGH2 to produce TxA2 (Fig. S6). Such
a GSH-promoted PGHS-catalysed formation of TxA2 is in line with
recent ﬁndings showing that extra-platelet GSH may enhance TxA2
synthesis in platelet-rich plasma [17]. It is worth mentioning that
the stereochemistry of TxA2 is prescribed in PGH2 [11] but not in
the opened cyclopentane-ring structure proposed by Ullrich et al.
[32].
The proposed reactions and their stoichiometry, in which GSH
participates either as a reductor (reactions (1)–(3)) or as a cata-
lyst (reaction (4); ‘‘[GSH]’’ indicates that GSH is not consumed),
are summarised below (see also Fig. S7). Considerable GSH oxi-
dation to GSSG would be associated with formation of MDA,
15(S)-8-iso-PGF2a, HNE and HHTrE. As MDA (and HNE) formation
rate is at least two orders of magnitude higher than that of
15(S)-8-iso-PGF2a and other F2-isoprostanes, the highest GSH
consumption rate in PGHS-catalysed reactions would result from
MDA formation (reactions (1) and (3)). The low-extent formation
of GSSG in the presence of the irreversible PGHS inhibitor ASA
suggests that this drug acts in such a way that peroxidation of
AA is not completely inhibited even at the high concentration
of 1000 lM.
AA-Triradicalþ 2GSH!MDAþHNEþ GSSG ð1Þ
AA-Triradicalþ 6GSH! 15ðSÞ-8-iso-PGF2a þ 3GSSG ð2Þ
AA-Monoradicalþ 2GSH!MDAþHHTrEþ GSSG ð3Þ
PGH2 þ ½GSH ! TxA2 þ ½GSH ð4Þ
In consideration of the antioxidant feature of GSH, the promo-
tion of PGHS-dependent formation of MDA and 15(S)-8-iso-PGF2a
from AA by GSH is paradoxical. This observation illustrates a
paradigm for an uncommon cooperation of enzymatic and chemi-
cal reactions to yield unexpected reaction products. MDA and
15(S)-8-iso-PGF2a are generally regarded as stable products formed
by the reaction of free radicals and AA esteriﬁed to lipids [3,4]. That
the antioxidant GSH promotes recombinant PGHS-dependentformation of MDA and 15(S)-8-iso-PGF2a from AA challenges the
utility of MDA and 15(S)-8-iso-PGF2a as reliable biomarkers of
oxidative stress. Assessment of circulating and/or excretory MDA
and 15(S)-8-iso-PGF2a, and possibly of HNE and HHTrE, may not
be proper biomarkers of oxidative stress in certain conditions.
These cases may include diseases associated with haemolysis and
platelets activation or inactivation, and administration of drugs
that inhibit PGHS activity such as aspirin [8], or drugs that may
affect GSH homoeostasis such as NAC, a GSH-prodrug, as shown
in the present study (Table 1).
As demonstrated by us here for MDA and 15(S)-8-iso-PGF2a and
by others elsewhere for MDA, 15(S)-8-iso-PGF2a and other
F2-isoprostanes and E2/D2-isoprostanes [33], many of the current
oxidative stress biomarkers are formed, at least in part, in the
course of enzyme-catalysed reactions, without being necessarily
associated with oxidative stress, and their production is promoted
by antioxidants including GSH. This is only rarely considered in this
area. The duality of oxidative stress biomarkers, i.e., their chemical
and enzymatic origin, seems to be a general phenomenon. It
represents a considerable methodological challenge and requires
proper consideration of potentially involved pathways and their
ramiﬁcations.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2012.
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